中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

1620 records (took 0.055 seconds)

    Maximizing efficiency of multi-user communications networks
    243.
    发明授权
    Maximizing efficiency of multi-user communications networks 有权
    最大限度地提高多用户通信网络的效率

    公开(公告)号：US09538483B2

    公开(公告)日：2017-01-03

    申请号：US14488028

    申请日：2014-09-16

    Applicant: The Regents of the University of Colorado, a body corporate

    Inventor： Lijun Chen ,  Xing Li ,  Youjian Liu

    IPC: H04W52/24 ,  H04B17/391 ,  H04W52/34

    CPC classification number: H04W52/243 ,  H04B17/391 ,  H04W52/346

    Abstract: Systems and methods are described for jointly optimizing communications in a multi-user network to maximize the weighted sum-rate of its data links. For example, embodiments seek to maximize overall link transmit rates, while minimizing link interference and/or noise in general multi-in multi-out (MIMO) interference networks having multiple interfering data links, each with one or more antennas at the transmitter and receiver. Novel algorithmic approaches, including an “iterative minimax” approach and a “dual link” approach, are described for solving the weighted sum-rate maximization in a manner that converges quickly and reliably on an optimal point. Some embodiments implement these approaches in a centralized transmission controller, while others implement these approaches in a distributed fashion.

    Abstract translation: 描述了用于联合优化多用户网络中的通信以最大化其数据链路的加权和率的系统和方法。 例如，实施例旨在最大化总体链路传输速率，同时在具有多个干扰数据链路的通用多进多输出（MIMO）干扰网络中最小化链路干扰和/或噪声，每个干扰数据链路在发射机和接收机处具有一个或多个天线 。 描述了新的算法方法，包括“迭代最小值”方法和“双链路”方法，以在最佳点上快速可靠地收敛的方式来求解加权和率最大化。 一些实施例在集中式传输控制器中实现这些方法，而其他实施例以分布式方式实现这些方法。

    Compositions and methods for treating hepatitis B
    246.
    发明授权
    Compositions and methods for treating hepatitis B 有权
    治疗乙型肝炎的组合物和方法

    公开(公告)号：US09518090B2

    公开(公告)日：2016-12-13

    申请号：US14431622

    申请日：2013-09-26

    Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE

    Inventor： Ding Xue ,  Xin Geng

    IPC: C07K7/08 ,  C07K7/06 ,  G01N33/50 ,  C12N15/113 ,  A61K38/00

    CPC classification number: A61K38/04 ,  A61K38/00 ,  C07K7/06 ,  C07K7/08 ,  C12N15/1131 ,  C12N15/1135 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2320/31 ,  C12N2330/50 ,  G01N33/5008 ,  G01N33/5085 ,  G01N2333/02 ,  G01N2500/02 ,  G01N2500/10

    Abstract: The present invention provides compositions and methods for treating hepatitis B virus (HBV) infection as well as methods for identifying a compound or a composition that is suitable for treating HBV infection. In addition, the present invention provides a suitable non-mammalian animal model that can be used to screen for a compound or a composition that can inhibit HBV replication or treat HBV infection in a mammal. In particular, the present invention provides compositions and methods for treating hepatitis B infection by inhibiting interaction between HBV x protein and a Bcl-2 family protein or by reducing the expression level of a Bcl-2 family protein.

    Abstract translation: 本发明提供用于治疗乙型肝炎病毒（HBV）感染的组合物和方法以及鉴定适合于治疗HBV感染的化合物或组合物的方法。 此外，本发明提供了可用于筛选可抑制哺乳动物HBV复制或治疗HBV感染的化合物或组合物的合适的非哺乳动物动物模型。 特别地，本发明提供通过抑制HBV x蛋白与Bcl-2家族蛋白之间的相互作用或通过降低Bcl-2家族蛋白的表达水平来治疗乙型肝炎感染的组合物和方法。

    All-Solid-State Cathode Materials, Cathodes, Batteries And Methods
    248.
    发明申请
    All-Solid-State Cathode Materials, Cathodes, Batteries And Methods 审中-公开
    全固态阴极材料，阴极，电池和方法

    公开(公告)号：US20160248082A1

    公开(公告)日：2016-08-25

    申请号：US15026195

    申请日：2014-09-30

    Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE

    Inventor： Thomas A. YERSAK ,  Tyler EVANS ,  Se-Hee LEE ,  Justin Michael WHITELEY

    IPC: H01M4/36 ,  H01M4/136 ,  H01M10/0525 ,  H01M4/58 ,  H01M10/0562

    CPC classification number: H01M4/364 ,  C01B17/22 ,  H01M4/136 ,  H01M4/5815 ,  H01M10/052 ,  H01M10/0525 ,  H01M10/0562 ,  H01M10/0563 ,  H01M2004/028

    Abstract: Described herein are various embodiments of methods of making an all-solid-state electrode material for a rechargeable battery comprising in a first mixing step, mixing one of a transition metal phosphide, a transition metal oxide, and a transition metal sulfide with sulfur to produce a first mixture, in a first heat-treating step, heating the first mixture to a temperature ranging between about 250 degrees C. and about 450 degrees C. to produce a heat-treated second mixture comprising an active material and a glass former/electrolyte precursor, in a second mixing step, mixing the second mixture with a glass/electrolyte modifier to produce a third mixture, and permitting the third mixture to react to produce the cathode material, the cathode material comprising the active material and a solid state electrolyte. Electrode materials, electrodes, and batteries made using the foregoing and similar methods are also described.

    Abstract translation: 本文描述了制备用于可再充电电池的全固态电极材料的方法的各种实施方案，其包括在第一混合步骤中，将过渡金属磷化物，过渡金属氧化物和过渡金属硫化物中的一种与硫混合以产生 第一混合物，在第一热处理步骤中，将第一混合物加热至约250摄氏度至约450摄氏度的温度，以产生热处理的第二混合物，其包含活性物质和玻璃形成物/电解质 前体，在第二混合步骤中，将第二混合物与玻璃/电解质改性剂混合以产生第三混合物，并允许第三混合物反应以产生阴极材料，阴极材料包含活性材料和固态电解质。 还描述了使用上述方法制造的电极材料，电极和电池。

    PREDICTION AND TREATMENT OF HEART FAILURE
    249.
    发明申请
    PREDICTION AND TREATMENT OF HEART FAILURE 审中-公开
    预防和治疗心脏衰竭

    公开(公告)号：US20160237498A1

    公开(公告)日：2016-08-18

    申请号：US15028117

    申请日：2014-10-03

    Applicant: The Regents of The University of Colorado, a body corporate

    Inventor： Michael BRISTOW ,  Carmen SUCHAROV ,  Matthew TAYLOR ,  Dobromir SLAVOV

    IPC: C12Q1/68

    CPC classification number: C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/156

    Abstract: Chronic activation of the β-Adrenergic Receptor (β-AR) can have deleterious effects on the heart, and animal models over-expressing the β-AR develop heart failure. In the classical β-AR pathway, activation of the receptor results in increased cyclic AMP(cAMP) levels. However, β-ARs are desensitized in the failing heart and cAMP levels are decreased. Phosphodiesterase 3A (PDE3A) hydrolyzes cAMP in certain subcellular compartments in cardiac myocytes, regulating cAMP levels and subsequent protein kinase A mediated cell signaling. By virtue of being freely diffusable intracellularly and being reduced in failing myocardial tissue, cAMP is reduced in certain important cardiac myocyte subcellular compartments such as the microdomain occupied by phospholamban.

    Abstract translation: β-肾上腺素能受体（β-AR）的慢性活化可对心脏产生有害作用，过度表达β-AR的动物模型会发展为心力衰竭。 在经典的β-AR途径中，受体的激活导致环AMP（cAMP）水平升高。 然而，β-AR在失败的心脏中脱敏，cAMP水平降低。 磷酸二酯酶3A（PDE3A）在心肌细胞的某些亚细胞区水解cAMP，调节cAMP水平和随后的蛋白激酶A介导的细胞信号传导。 由于在细胞内自由扩散并且在失败的心肌组织中减少，在某些重要的心肌细胞亚细胞区域中，cAMP被减少，例如由磷胆碱占据的微区域。

Patent Agency Ranking